Procedures Segment, by Type, to Account Larger Share Microbiome Therapeutics Market During 2022–2030 

According to our new research study on "Microbiome Therapeutics Market Size and Forecast (2020–2030), Global and Regional Share, Trends, and Growth Opportunity Analysis," the microbiome therapeutics market size is expected to grow from US$ 375.92 million  in 2022 and to reach a value of US$ 813.38 million by 2030; it is anticipated to record a CAGR of 10.1% from 2022 to 2030. Key factors driving the market growth are potential of gut microbiota in maintaining human health and inflow of funds to ameliorate microbiome discovery pipeline. However, high cost of development and production hinders the microbiome therapeutics market growth.

Microbiome therapeutics, also referred to as microbiome-based therapies or interventions, are medical procedures that try to use the human microbiome's potential to treat and promote a variety of illnesses. In the healthcare and life science industries, microbiome therapeutics are a new and quickly expanding market. This market is being driven by advancements in microbiome research, which are raising awareness of the gut-brain connection and offering the possibility of developing cutting-edge treatments for a range of medical conditions. The pipeline of microbiome therapeutics is dynamic and diverse, aimed at tackling an extensive array of medical conditions and offering novel treatments that harness the human microbiome. More microbiome-based treatments may become available as this field of study develops, opening up new avenues for market expansion. There is a growing need for novel and more efficient treatments due to the rising prevalence of illnesses like metabolic disorders, obesity, irritable bowel syndrome, and inflammatory bowel disease. Microbiome-based treatments present a cutting-edge method of treating these ailments. This consequently generates a large window of opportunity for market expansion in the near future.
 
Based on type, the microbiome therapeutics market is segmented into therapeutics and procedures. The therapeutics segment is further bifurcated into faecal microbiota transplantation (FMT), prebiotics & probiotics, and others. Fecal microbiome therapeutic technique is an emerging technique that has proven to be highly effective in patients with recurring Clostridioides difficile infection (CDI). Growing FMT product approvals by the Food and Drug Administration (FDA) for preventing the recurrence of CDI is fueling the growth of the segment. For instance, in November 2022, the US FDA approved Rebyota, the first fecal microbiota product used for the prevention of CDI recurrence in individuals aged above 18 years.

Based on the application, the microbiome therapeutics market is classified into metabolic disorders and obesity, C. difficile infection, inflammatory bowel diseases, and others. In 2022, the C. difficile infection segment held the largest share of the market and is expected to register the highest CAGR during 2022–2030. When someone takes antibiotics, good bacteria in the gut are destroyed for a few months. During this time, patients can get sick from Clostridioides difficile, a bacteria that often causes severe or even deadly diarrhea. According to CDC, in 2021, ~118,000 hospitalized patients suffered from C. difficile infection in the US. To prevent and treat C. difficile infection, the gut microbiome of the patient needs to be increased by giving microbiome therapeutics. Due to the increase in the number of C. difficile infections, companies are focusing on developing microbiome therapeutics for the treatment. For instance, in April 2023, the US FDA approved Vowst, the first fecal microbiota used to prevent the recurrence of C. difficile infection.

Based on the end user, the microbiome therapeutics market is classified into hospitals and clinics, ambulatory surgery centers, home care, and others. In 2022, the hospitals and clinics segment held the largest share of the market, and it is expected to register the highest CAGR during 2022–2030. Hospitals are the fastest-growing end users of the microbiome therapeutics market. Hospitals are the primary healthcare centers patients seek for their first aid and treatment. The number of patients visiting hospitals is comparatively higher than other healthcare centers. These centers offer various services and provide good-quality treatment to patients. In many hospitals, the treatment fee is reimbursed; also, medicines are readily available in these healthcare centers. The implementation of advanced treatment technologies in hospitals has paved the way for improved and early detection of disease, as well as supported research related to disease treatment. Medical services are increasingly offered due to their rising affordability of treatment and awareness among people. It is a part of the ecosystem of many countries, as it contributes significantly toward the country’s GDP growth.
 
Enterome, Finch Therapeutics Group Inc, Caelus Health, Ferring Pharmaceuticals, Pendulum Therapeutics Inc., AOBiome, Seres Therapeutics, Vedanta Biosciences, COST-BRY Pty Ltd (BiomeBank) and YSOPIA Bioscienceare. are among the leading companies operating in the global microbiome therapeutics market.    

Companies operating in the microbiome therapeutics adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies in the microbiome therapeutics. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall microbiome therapeutics growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.
 
A few of the significant developments by key market players are listed below.

• In November 2023, the company obtained its first worldwide regulatory approval for a donor-derived microbiome medicinal product in November 2022 from the Therapeutic Goods Administration (TGA). 
• In February 2023, Ferring Pharmaceuticals has announced that RBX2660, also known as Rebyota, is a fecal microbiota product that can be used for treatment in the United States. Ferring has provided adults with a much-needed new therapeutic option for recurrent C diff infection with the introduction of Rebyota. The introduction of this revolutionary live biotherapeutic based on microbiota offers an innovative approach to treating people with recurrent C diff (CDI) infection.

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com